12 avr. 2023
Vergio celebrates its first year of activity with major achievements
Vergio is happy to celebrate its first year of activity with important achievements over the last 12 months:
The report together with international researchers on a phase 3 study published in an international journal https://journals.sagepub.com/doi/10.1177/02698811221104063
The preparation of clinical modules for a compound targetting a life-threatening disease with a high unmet medical need
The conduct with international researchers of a network meta-regression published in an international journal https://academic.oup.com/alcalc/article/58/2/125/6972911?login=false
The review of statistical analyses of a phase 3 study and the medical writing of the clinical study report
Review of clinical sections of a briefing package for pre-IND meeting and participation in the discussion with the US FDA
The conduct of a meta-analysis and a meta-regression to estimate the fatality rate with the standard therapy for an infectious disease and intended to be submitted to the European Medicines Agency
We like to thank all internal and external people involved in these projects and we look forward to pursuing our efforts to provide value and solutions to our clients.